

September 25, 2017

Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting

SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, November 8-12, 2017 in National Harbor, Maryland.

The oral and poster presentation information are as follows:

Novel Biomarkers in Next-generation Cancer Vaccines

Public NY-ESO-1 specific TCRs as novel biomarkers for immune monitoring of NY-ESO-1 positive cancer patients

Oral Presentation/ SITC Pre-Conference Program

Session title: Immuno-Oncology Biomarkers: Today's Imperatives for Tomorrow's Needs

Date: November 8, 2017

Time: 8 a.m. to 12:30 p.m.

Presenter: Hailing Lu, MD, PhD, Principal Scientist, Immune Design

Poster Presentation:

Poster Number: P58

Date: Saturday, November 11, 2017

Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.

Presenter: Hailing Lu, MD, PhD, Principal Scientist, Immune Design

Combination Therapy (Cancer Vaccine + Intratumoral Immunization):

G100 and ZVex[®]-based combination immunotherapy induces near complete regression of established glioma tumors in mice

Poster Number: P256

Date: Saturday, November 11, 2017

Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.

Presenter: Tina Chang Albershardt, PhD, Scientist II, Immune Design

Multi-Target Cancer Vaccines:

Transduction of MAGE-A1, A3, A4, A10 and IL-12 by ZVex[®], a dendritic cell targeting platform induces robust multi-antigen T-cell immune responses without antigenic interference or immunodominance

Poster Number: P127

Date: Friday, November 10, 2017

Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.

Presenter: Jardin Leleux, Postdoctoral Researcher, Immune Design

Next-Generation Intratumoral Vaccination Using ZVex:

Intratumoral expression of IL12 using the ZVex[®] dendritic cell-targeting lentiviral vector exerts potent anti-tumor effects via induction of multiple immune effectors, including CD8 T cell responses

Poster Number: P401

Date: Friday, November 10, 2017

Time: 12:30 — 2 p.m. and 6:30 — 8 p.m.

Presenter: Tina Chang Albershardt, PhD, Scientist II, Immune Design

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two leading product candidates focused in cancer immunotherapy, are the first products from Immune Design's two separate discovery platforms targeting dendritic cells in vivo, ZVex® and GLAAS®. Both ZVex and GLAAS also have potential applications in infectious disease and allergy as demonstrated by ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.

Media Contact

Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219

Investor Contact

Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902